Article
Endocrinology & Metabolism
Chi Wang, Hebin Che, You Zhou, Ruiqing Wang, Di Zhu, Liting Cheng, Chongyou Rao, Qin Zhong, Zongren Li, Yongjie Duan, Jiayu Xu, Wei Dong, Yongyi Bai, Kunlun He
Summary: This retrospective cohort study investigated the joint association of hyperuricemia and chronic kidney disease (CKD) with mortality in patients with chronic heart failure (CHF). The results showed that both hyperuricemia and CKD were independently associated with increased in-hospital and long-term mortality risk in CHF patients. These findings highlight the importance of managing hyperuricemia and CKD together in the management of heart failure.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Transplantation
Shijie Wu, Wen Xue, Hanqing Yu, Hanjie Yu, Zhaoqiang Shi, Ling Wang, Ai Peng
Summary: This study investigated the relationship between serum uric acid concentrations and mortality risk among patients with chronic kidney disease (CKD). The results demonstrated J-shaped non-linear relationships between uric acid concentrations and all-cause and cardiovascular disease mortality, with inflection points at 311.65 mu mol/L and 392.34 mu mol/L, respectively. Furthermore, a negative linear correlation with cancer mortality was observed. The study suggests that maintaining appropriate uric acid concentrations may improve long-term health outcomes among CKD patients.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Hematology
Jialing Zhang, Xiangxue Lu, Han Li, Shixiang Wang
Summary: The study found that both higher and lower levels of SUA in CKD patients are significantly associated with increased all-cause mortality, highlighting the need to confirm the appropriate dose of treatment with SUA-lowering agents.
BLOOD PURIFICATION
(2021)
Article
Geriatrics & Gerontology
Thomas J. Wilkinson, Joanne Miksza, Francesco Zaccardi, Claire Lawson, Andrew C. Nixon, Hannah M. L. Young, Kamlesh Khunti, Alice C. Smith
Summary: Frailty is common in individuals with chronic kidney disease (CKD) and is associated with adverse outcomes, including mortality and risk of end-stage kidney disease (ESKD). Preventative interventions should be initiated to mitigate the development of frailty. The use of a simple frailty index, generated electronically from health records, can predict outcomes and may aid prioritization for management of people with frailty.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Article
Medicine, General & Internal
Peng-Tzu Liu, Jong-Dar Chen
Summary: This study evaluated the association of HHcy and hyperuricemia with CKD in middle-aged and elderly populations in Taiwan, finding that both HHcy and hyperuricemia are independent risk factors for CKD with a significant synergistic association. The odds ratios of CKD increased with the quartiles of Hcy, independent of hyperuricemia, and hyperuricemia and HHcy showed a synergistic association with CKD.
Article
Pediatrics
Yuanyuan Xu, Xiaohong Zheng, Hongjie Zhuang, Hongyi Liao, Ying Mo, Xiaoyun Jiang, Wen Li
Summary: This study aims to explore potential biomarkers and risk factors in children with IgA nephropathy (IgAN). The results showed that hyperuricemia is closely related to the progression and poor renal outcome of IgAN in children. It is important to pay attention to hyperuricemia in children with IgAN, especially in females.
PEDIATRIC RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Sung-Bum Lee, Hui-Jeong Lee, Ha Eun Ryu, Byoungjin Park, Dong-Hyuk Jung
Summary: Multiple studies have shown that hyperuricemia is associated with the development of ischemic heart disease (IHD). Additionally, there is growing evidence suggesting that hyperuricemia may contribute to the progression of IHD as a pathogenic factor. Ironically, uric acid can also act as an antioxidant, as demonstrated in experimental studies. The aim of this study was to analyze the association between uric acid and IHD in patients with early-stage chronic kidney disease (CKD).
Article
Multidisciplinary Sciences
Young-Bin Son, Ji Hyun Yang, Myung-Gyu Kim, Sang Kyung Jo, Won Yong Cho, Se Won Oh
Summary: The study found that serum uric acid is positively correlated with systolic blood pressure, triglycerides, body mass index, and body fat percentage. Additionally, it is inversely associated with high density lipoprotein (HDL) and is an independent risk factor for the development of diabetes, hypertension, and obesity. High levels of uric acid are also associated with increased risk of chronic kidney disease (CKD) development and decline in estimated glomerular filtration rate (eGFR) in individuals with normal kidney function.
Article
Pharmacology & Pharmacy
Ya-Lien Cheng, Shu-Chun Huang, Ming-Yun Ho, Yan-Rong Li, Chieh-Li Yen, Kuan-Hsing Chen, Wei-Chiao Sun, Pei-Yi Fan, Jung-Sheng Chen, Chihung Lin, Ching-Chung Hsiao
Summary: Metabolic acidosis is a common complication in chronic kidney disease (CKD) patients. This study found that the use of sodium bicarbonate in patients with advanced CKD was associated with similar risk of dialysis initiation but significantly lower risks of major adverse cardiovascular events (MACE) and mortality. The findings highlight the benefits of sodium bicarbonate therapy in the CKD population.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Katsunori Yanai, Keiji Hirai, Shohei Kaneko, Yuko Mutsuyoshi, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita
Summary: We retrospectively analyzed the efficacy and safety of dotinurad, a selective urate reabsorption inhibitor, in hyperuricemic patients with advanced CKD. The results showed that dotinurad was able to decrease uric acid levels and might attenuate renal function decline.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Review
Nutrition & Dietetics
Nicoline H. J. Leenders, Emma A. Vermeulen, Adriana J. van Ballegooijen, Tiny Hoekstra, Ralph de Vries, Joline W. Beulens, Marc G. Vervloet
Summary: This study aimed to evaluate the association of plasma magnesium concentration with clinically relevant outcomes in chronic kidney disease patients. The results showed that higher magnesium levels were associated with a lower risk of all-cause mortality, cardiovascular mortality, and events.
CLINICAL NUTRITION
(2021)
Review
Urology & Nephrology
Hans-Joachim Anders, Qiubo Li, Stefanie Steiger
Summary: Asymptomatic hyperuricaemia (HU) is linked to multiple diseases, but only gouty arthritis and urate nephropathy have proven causative relationships with uric acid crystals. Epidemiological studies show a strong association between HU and hypertension, cardiovascular disease (CVD), and CKD progression, but impaired UA clearance and the use of diuretics likely contribute to these associations. This review provides new insights into the effects of soluble and crystalline UA, discusses the role of asymptomatic HU in CKD, CVD, and sterile inflammation, and identifies areas of research that require further investigation.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Urology & Nephrology
Fengqin Li, Hui Guo, Jianan Zou, Chensheng Fu, Song Liu, Jing Xiao, Zhibin Ye
Summary: The classification of hyperuricemia (HUA) with chronic kidney disease (CKD) can be varied significantly based on different combinations of parameters such as urinary uric acid excretion rate with uric acid clearance rate or 24-hour urinary uric acid with fractional excretion of uric acid. Further research is needed to determine the most applicable classification method for HUA patients with CKD.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2021)
Review
Peripheral Vascular Disease
Hitoshi Nishizawa, Norikazu Maeda, Iichiro Shimomura
Summary: Hyperuricemia is caused by a combination of reduced excretion and overproduction of uric acid, with potential complications including gout, hypertension, CKD, and CVD. Mechanisms such as inflammasome activation and oxidative stress are proposed to contribute to renal damage and atherosclerosis in hyperuricemia, highlighting the need for further research on purine metabolism and treatment strategies.
HYPERTENSION RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Ching-Chung Hsiao, Jih-Kai Yeh, Yan-Rong Li, Wei-Chiao Sun, Pei-Yi Fan, Chieh-Li Yen, Jung-Sheng Chen, Chihung Lin, Kuan-Hsing Chen
Summary: The study shows that the de novo use of statins in patients with non-dialysis CKD stage V can reduce the incidence of cardiovascular events, hospitalization, and mortality for infectious disease. The results reinforce the benefits of statins in a wide range of patients with renal impairment before maintenance dialysis.
FRONTIERS IN PHARMACOLOGY
(2022)